Introduction: Immunosuppressive agents (ISA) have been used in multiple sclerosis (MS) for decades, frequently as off label licensed therapies. Given the new MS treatment landscape, what place do ISA have in combating MS? Methods: We conducted a retrospective multicentre study to investigate the frequency of ISA prescription in 17 Italian MS centres, and to describe the clinical factors related to ISA use. Results: Out of 6,447 MS patients, 2,034 (31.6%) were treated with ISA, with Azathioprine being the most frequently used ISA overall. MS patients treated with ISA alone were more frequently affected by the progressive course (both primary and secondary) of the disease (RRR 5.82, 95% CI 4.14–8.16, p<0.0001), had higher EDSS (RRR 3.69, 9...
BackgroundIn multiple sclerosis (MS), bridging therapies are usually administered when switching fro...
Background: The increase in disease-modifying drugs (DMDs) allows individualization of treatment in ...
OBJECTIVE: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-...
Introduction Immunosuppressive agents (ISA) have been used in multiple sclerosis (MS) for decades, f...
Immunosuppressive agents (ISA) have been used in multiple sclerosis (MS) for decades, frequently as ...
none6Background: Current treatment of multiple sclerosis (MS) with disease-modifying drugs (DMDs) i...
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system with an imm...
BACKGROUND: The availability of new disease-modifying treatments (DMTs) in the last years has chang...
OBJECTIVE: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-...
Background: Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increa...
Background: Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increa...
Introduction: Therapeutic armamentarium in Multiple Sclerosis (MS) has radically changed in the last...
This cross-sectional study has investigated the diagnostic and therapeutic management of patients su...
Background: Few studies have analysed long-term effects of immunomodulatory disease modifying drugs ...
OBJECTIVE: The introduction of oral disease-modifying drugs (DMDs) in addition to the available, inj...
BackgroundIn multiple sclerosis (MS), bridging therapies are usually administered when switching fro...
Background: The increase in disease-modifying drugs (DMDs) allows individualization of treatment in ...
OBJECTIVE: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-...
Introduction Immunosuppressive agents (ISA) have been used in multiple sclerosis (MS) for decades, f...
Immunosuppressive agents (ISA) have been used in multiple sclerosis (MS) for decades, frequently as ...
none6Background: Current treatment of multiple sclerosis (MS) with disease-modifying drugs (DMDs) i...
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system with an imm...
BACKGROUND: The availability of new disease-modifying treatments (DMTs) in the last years has chang...
OBJECTIVE: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-...
Background: Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increa...
Background: Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increa...
Introduction: Therapeutic armamentarium in Multiple Sclerosis (MS) has radically changed in the last...
This cross-sectional study has investigated the diagnostic and therapeutic management of patients su...
Background: Few studies have analysed long-term effects of immunomodulatory disease modifying drugs ...
OBJECTIVE: The introduction of oral disease-modifying drugs (DMDs) in addition to the available, inj...
BackgroundIn multiple sclerosis (MS), bridging therapies are usually administered when switching fro...
Background: The increase in disease-modifying drugs (DMDs) allows individualization of treatment in ...
OBJECTIVE: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-...